86 related articles for article (PubMed ID: 22317866)
1. Histological grading of ovarian clear cell adenocarcinoma: proposal for a simple and reproducible grouping system based on tumor growth architecture.
Yamamoto S; Tsuda H; Shimazaki H; Takano M; Yoshikawa T; Kuzuya K; Tsuda H; Kurachi H; Kigawa J; Kikuchi Y; Sugiyama T; Matsubara O
Int J Gynecol Pathol; 2012 Mar; 31(2):116-24. PubMed ID: 22317866
[TBL] [Abstract][Full Text] [Related]
2. Clear cell adenocarcinoma with a component of poorly differentiated histology: a poor prognostic subgroup of ovarian clear cell adenocarcinoma.
Yamamoto S; Tsuda H; Shimazaki H; Takano M; Yoshikawa T; Kuzuya K; Tsuda H; Kurachi H; Kigawa J; Kikuchi Y; Sugiyama T; Matsubara O
Int J Gynecol Pathol; 2011 Sep; 30(5):431-41. PubMed ID: 21804390
[TBL] [Abstract][Full Text] [Related]
3. Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group.
Yamamoto S; Kasajima A; Takano M; Yaegashi N; Fujiwara H; Kuzuya K; Kigawa J; Tsuda H; Kurachi H; Kikuchi Y; Sugiyama T; Tsuda H; Moriya T
Int J Gynecol Pathol; 2011 Mar; 30(2):129-38. PubMed ID: 21293288
[TBL] [Abstract][Full Text] [Related]
4. Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary.
Sekiya R; Kajiyama H; Sakai K; Umezu T; Mizuno M; Shibata K; Yamamoto E; Fujiwara S; Nagasaka T; Kikkawa F
Hum Pathol; 2012 Jun; 43(6):904-10. PubMed ID: 22169254
[TBL] [Abstract][Full Text] [Related]
5. Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics.
Yamamoto S; Tsuda H; Yoshikawa T; Kudoh K; Kita T; Furuya K; Tamai S; Matsubara O
Am J Surg Pathol; 2007 Jul; 31(7):999-1006. PubMed ID: 17592265
[TBL] [Abstract][Full Text] [Related]
6. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
7. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma.
Scholten AN; Smit VT; Beerman H; van Putten WL; Creutzberg CL
Cancer; 2004 Feb; 100(4):764-72. PubMed ID: 14770433
[TBL] [Abstract][Full Text] [Related]
10. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.
Gilks CB; Ionescu DN; Kalloger SE; Köbel M; Irving J; Clarke B; Santos J; Le N; Moravan V; Swenerton K;
Hum Pathol; 2008 Aug; 39(8):1239-51. PubMed ID: 18602670
[TBL] [Abstract][Full Text] [Related]
11. Pathological classification and grading of primary ovarian carcinoma: experience of the ARTAC ovarian study group.
Vacher-Lavenu MC; Le Tourneau A; Duvillard P; Godefroy N; Pinel MC
Bull Cancer; 1993 Feb; 80(2):135-41. PubMed ID: 8173164
[TBL] [Abstract][Full Text] [Related]
12. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases.
Veras E; Mao TL; Ayhan A; Ueda S; Lai H; Hayran M; Shih IeM; Kurman RJ
Am J Surg Pathol; 2009 Jun; 33(6):844-53. PubMed ID: 19342944
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
14. Histologic correlates of progression-free interval and survival in ovarian clear cell adenocarcinoma.
Kennedy AW; Biscotti CV; Hart WR; Tuason LJ
Gynecol Oncol; 1993 Sep; 50(3):334-8. PubMed ID: 8406197
[TBL] [Abstract][Full Text] [Related]
15. Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3.
Min KW; Park MH; Hong SR; Lee H; Kwon SY; Hong SH; Joo HJ; Park IA; An HJ; Suh KS; Oh HK; Yoo CW; Kim MJ; Chang HK; Jun SY; Yoon HK; Chang ED; Kim DW; Kim I;
Int J Gynecol Pathol; 2013 Jan; 32(1):3-14. PubMed ID: 23202783
[TBL] [Abstract][Full Text] [Related]
16. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0).
Sakuragi N; Yamada H; Oikawa M; Okuyama K; Fujino T; Sagawa T; Fujimoto S
Gynecol Oncol; 2000 Nov; 79(2):251-5. PubMed ID: 11063653
[TBL] [Abstract][Full Text] [Related]
18. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary.
Mizuno M; Kikkawa F; Shibata K; Kajiyama H; Ino K; Kawai M; Nagasaka T; Nomura S
J Surg Oncol; 2006 Aug; 94(2):138-43. PubMed ID: 16847906
[TBL] [Abstract][Full Text] [Related]
20. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
